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Abstract In this study we provide evidence that tamoxifen, the 
widely used breast cancer drug, is a potent antagonist of 
glycolipid metabolism. When added to the medium of cultured 
multidrug resistant (MDR) KB-V-I carcinoma cells, tamoxifen, 
at 5.0 pM, drastically lowered the levels of glucosylceramide 
(glc-cer), as evidenced by a reduction in glc-cer mass. In a similar 
fashion, in cultured human melanoma cells grown with 
[3H]galactose, tamoxifen inhibited formation of glc-cer by 
44%, and retarded lactosylceramide and ganglioside formation 
by 50 and 35%, respectively. When glc-cer synthase of melanoma 
was assayed in cell-free incubations, the inclusion of tamoxifen, 
at a I :I0 molar ratio with ceramide, inhibited glc-cer synthesis 
by 50%. These results clearly reveal a new action of tamoxifen 
and thereby pose intriguing questions regarding mechanisms of 
action in the realm of estrogen receptor-independent modalities, 
including effects on MDR. 
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1. Introduction 
The efficacy of tamoxifen, used for treatment of estrogen 
receptor-positive breast cancer, lies chiefly in its ability to 
antagonize the action of estrogen by binding competitively 
to the estrogen receptor [1,2]. It has, however, become increas- 
ingly apparent hat many biological activities of tamoxifen are 
potentiated in a manner divorced from estrogen receptor ma- 
chinery [3]. Examples of activities promoted by tamoxifen in- 
clude protection against lipid peroxidation [4], induction of 
transforming rowth factor-[3 [5], modification of protein ki- 
nase C activity [6 8], activation of lipid second messenger 
signaling [9], and antagonism of calmodulin [10]. Along these 
lines, the utility of tamoxifen in non-breast related disease, 
e.g. brain [11] and melanoma [12], has sparked interest and 
elicited a move to understand the multimodal mechanisms of 
action of this synthetic triphenylethylene [3]. Among the most 
intriguing properties of tamoxifen, independent of estrogen 
receptor status, is reversal of multidrug resistance (MDR) 
[3,13,14]. This has resulted in clinical studies (1/ aimed at ex- 
ploiting the chemosensitizing properties of tamoxifen [15,16]. 
We have recently demonstrated that specific glycosphingo- 
lipids, identified as glucosylceramides (glc-cer), accumulate in 
MDR cancer cells [17]. This finding poses new questions re- 
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garding the role of lipids in MDR neoplasms. As gleaned 
from the literature, it is now clear that tamoxifen impacts 
on cellular lipid metabolism [9,18 20] and on P-gp-dependent 
and -independent modes of MDR [21-23]. The association of 
tamoxifen with MDR reversal then becomes more interesting 
when considering the participation of lipids in drug transport. 
Reports have shown that P-gp ATPase activity is dependent 
on lipid environment [24], and that lipids interact with P-gp 
substrates [25]. 
Although tamoxifen has been shown to influence various 
aspects of lipid metabolism in intact cells and tissues, a direct 
impact on the enzymes of lipid metabolism has not been 
clearly evidenced. Herein we report that tamoxifen inhibits 
glucosylceramide synthase. As such, tamoxifen takes on a 
new role as a regulator of glycolipid metabolism. Because 
tamoxifen is used widely for treatment and for prevention 
of breast cancer and related compounds are making an ap- 
pearance in the clinic, knowledge must be gained regarding 
the biological actions of these agents. Our results show that 
tamoxifen can exert considerable xtra-nuclear influence. The 
impact of tamoxifen on ceramide glycosylation may be impor- 
tant in defining mechanisms underlying various aspects of 
tamoxifen action. Herein we offer some insight. 
2. Materials and methods 
2.1. Materials 
Ceramide (brain) and phosphatidylcholine (dioleoyl) were from 
Avanti Polar Lipids (Alabaster, AL). Sulfatides (ceramide galactoside 
3-sulfate, bovine) and glucosylceramide (Gaucher's pleen) were pur- 
chased from Matreya (Pleasant Gap, PA). o-[6-3H]Galactose (29.5 Ci/ 
mmol) was from DuPont NEN, and uridine diphosphate 
[6-3H]glucose (15 Ci/mmol) was purchased from American Radio- 
labeled Chemicals (St. Louis, MO). Dithiothreitol, [~-NAD, tamoxifen 
(free base), estradiol and UDP-glucose (disodium salt) were from 
Sigma. 4-hydro.~v-Tamoxifen was a gift from Dr. Dominique Salin- 
Drouin of Besins Iscovesco Laboratories (Paris, France). Silica gel G 
TLC plates were purchased from Analtech (Newark, DE), and sol- 
vents were from Fisher. RPMI-1640 medium was from Mediatech 
(Herndon, VA), and FBS was from Hyclone (Logan, UT). Tissue 
culture ware was purchased from Falcon. 
2.2. Cell culture 
The MDR cell line, KB-V-I, was kindly provided by Dr. Michael 
M. Gottesman, National Cancer Institute. The melanoma cell line, M- 
10, was established from human tumor [26]. Cells were grown in 
RPMI-1640 containing 10% FBS (v/v), 50 units/ml penicillin, 50 lag/ 
ml streptomycin, and 584 mg/1 L-glutamine, and subcultured as de- 
scribed [17]. 
Cells (at 60-70% confluence) were treated with tamoxifen (5.0 laM) 
for 24 h in medium containing 5% FBS. Tamoxifen, in acetone, was 
added from a 20 mM stock solution; acetone vehicle was present in 
controls. When utilized, [3H]galactose was introduced at a concentra- 
tion of 2.0 laCi/ml medium. Cells were harvested by removing me- 
dium, rinsing the monolayer twice with ice-cold phosphate-buffered 
saline, and scraping in ice-cold methanol containing 2% acetic acid. 
Lipid extraction [27] was continued in 1-dram glass vials with teflon- 
lined screw caps. The lower phase (biphasic extraction) containing 
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total cell lipids was taken to dryness under a stream of nitrogen and 
analyzed. 
2.3. Glucosylceramide synthase assay 
Enzyme activity was assayed (M-10 cell homogenate) according to 
the method of Shukla and Radin [28], and tamoxifen was added to the 
lipoidal substrate. Components of the lipoidal substrate, after solvent 
evaporation under nitrogen, were immediately sonicated in water and 
used. Enzyme was prepared from M-10 cells by rinsing monolayers 
three times with ice-cold phosphate-buffered saline and scraping cells 
in ice-cold water (0.5 ml per 10 cm culture dish). The cellular prepara- 
tion was sonicated, over ice, for 15 s. Protein was determined using 
the Pierce BCA Protein Assay Reagent. Enzyme incubations were 
carried out at 37°C in a shaking water bath, for 90 rain. 
2.4. Lipid analysis' 
Glc-cer was resolved from other cell lipids by TLC in a solvent 
system containing chloroform/methanol/ammonium hydroxide 
(40:10:1, v/v). The radiolabeled glc-cer was scraped from the TLC 
plate, after visualization in iodine vapor, and analyzed in Ecolume 
fluid, by liquid scintillation spectrometry. Radiolabeled lactosylcer- 
amide and gangliosides were isolated and resolved by TLC as de- 
scribed [17]. To char lipids for mass quantitation, the TLC plates 
were sprayed with 30% sulfuric acid and heated in an oven at 
180°C for 20 min. 
Analysis of [3H]glc-ser formed in cell-free assays was done by first 
terminating the reaction by addition of lipid extraction solvents [27]. 
After evaporating the lower phase (under nitrogen), 50 lal chloroform/ 
methanol (1:1, v/v) was added to the sample and a 10 ~tl aliquot was 
applied to TLC. Commercial glc-cer (5-10 lag) was co-spotted. The 
[3H]glc-cer was resolved in the above solvent system, and radio- 
analysis was by liquid scintillation spectrometry. 
0 
The structure of tamoxifen, a synthetic nonsteroidal tri- 
phenylethylene derivative, is shown in Fig. 1. A l though clas- 
sified as an antiestrogen, this drug has complex actions [3]. In 
previous work [17], we learned that specific glycolipids (glc- 
cer) accumulate in MDR cancer cells. Among the cells ewtl- 
uated were drug resistant breast cancer cells, and in these cells 
we noted that glc-cer levels were reduced upon exposure to 
tamoxifen. We sought to further explore this response in other 
MDR cells, most notably, melanoma, for which tamoxifen is 
a component  of a combinat ion chemotherapy regimen [12]. 
Fig. 2 demonstrates the glc-cer profile in KB-V-1 carcinoma 
cells that are grown in the absence and presence of tamoxifen. 
As shown in the right lane, tamoxifen, over a 24 h exposure 
..... ~- -  N(CH3) 2 
Tamoxifen 
Fig. 1. The chemical structure of tamoxifen. 
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Fig. 2. Thin-layer chromatographic char of glucosylceramide levels 
in KB-V-1 cells grown in the absence and presence of tamoxifen. 
Cultures (10 cm dishes) were grown to 60 70% confluence and tam- 
oxifen (5.0 laM) was added, where indicated, for 24 h. TLC chars 
were conducted as described in Section 2. A representative char 
from the cerebroside area of the TLC plate is shown. A: glc-cer 
commercial standard; B: M-10 cell levels of glc-cer (grown without 
tamoxifen); C: cell glc-cer levels grown in presence of tamoxifen. 
3. Results 
period, drastically reduced the levels of cellular glc-cer. Over 
this same time period, the drug caused no significant change 
in cell number. These results show that tamoxifen can inter- 
fere with glycolipid metabol ism in intact cells. 
Using radiolabeled human melanoma (M-10 cells), we 
sought to confirm the influence of tamoxifen on glc-cer metab- 
olism and, as well, assess cerebroside and ganglioside metab- 
olism. As shown in Fig. 3, the addition of tamoxifen, to cul- 
tures of human melanoma, inhibited biosynthesis of glc-cer by 
44%, based on trit ium incorporated from [3H]galactose. Tam- 
oxifen also caused diminished lactosylceramide and ganglio- 
side formation, 50 and 35%, respectively. The results from 
Figs. 2 and 3 strongly indicate that tamoxifen is an antagonist 
of glycolipid metabolism. Estradiol, tested at 5.0 nM and 
5.0 gM, in M-10 cells under the conditions described in 
Fig. 3, was without influence. 
To directly evaluate the influence of tamoxifen on glycolipid 
synthesis, we measured the effect of the drug on glucosylcer- 
amide synthase, the enzyme responsible for the first com- 
mitted step of glycolipid synthesis. Table 1, using a crude 
enzyme preparation from melanoma cells, shows that tam- 
oxifen inhibited ceramide glycosylation in the cell-free assay. 
Compared to control, tamoxifen, at a 1:20 molar ratio with 
ceramide, inhibited glc-cer synthesis by 32% (Table 1). The 
inhibit ion was dose-dependent, as shown by the near 50% 
reduction in glc-cer synthesis when tamoxifen was present at 
higher amounts (1:10 molar ration with ceramide). Interest- 
ingly, 4-hydroxy-tamoxifen, a major in vivo metabolite, of 
Table 1 
The influence of tamoxifen and 4-hydroxy-tamoxifen on cell-free 
glucosylceramide synthase activity in melanoma cell preparations 
Addition Glc-cer synthase activity (pmol 
glc-cer formed/mg protein) 
Control 2967 + 57 
Tamoxifen (1:20) 2013 _+ 167 
Tamoxifen (1 : 10) 1604 _+ 70 
4-hydroxy-Tamoxifen (1 :10) 2486 _+ 118 
Glc-cer synthase was assayed as described [28], using M-10 melanoma 
cell homogenate (130 lag protein/reaction) i  a final volume of 0.2 ml. 
Incubations were for 90 min at 37°C. Numbers in parentheses denote 
the molar ratio of drug to ceramide in the reaction mixture. The 
mean+ S.D. of triplicate determinations is shown. Enzyme experi- 
ments were repeated many times with the same results. 
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Fig. 3. Tamoxifen retards glycolipid synthesis in human melanoma 
cells. Cells (M-10), grown to 60-70% confluence, were switched to 
medium containing 5'¼, FBS and cultured for 24 h, without or with 
tamoxifen (5.0 [aM), in medium containing [3H]galactose (2.0 ~Ci/ 
ml). Cell harvest, extraction, and TLC analyses of radiolabeled gly- 
colipids were conducted as described in Section 2. ( - )  indicates no 
tamoxifen; (+) indicates with tamoxifen. 
rather minor chemical modification, was not nearly as effec- 
tive as tamoxifen in blocking glc-cer synthesis (16% inhibi- 
tion). 
4. Discussion 
Our results, presenting evidence that tamoxifen antagonizes 
glycolipid metabolism, are based upon (i) depletion of glc-cer 
levels in KB-V-I cells grown in the presence of tamoxifen in 
the culture medium; (ii) reduced utilization of [3H]galactose 
for synthesis of cerebrosides and gangliosides in cultured hu- 
man melanoma cells; (iii) inhibition of glc-cer formation in 
cell-free assays of glc-cer synthase. In experiments with intact 
cells, drug had no influence on uptake of radio precursors. 
This study brings to light a new activity, one beyond the 
antiestrogen [3], for the popular chemotherapeutic agent tam- 
oxifen. 
Glycolipids exert major influence over cell growth, differen- 
tiation, and transformation [29,30], and as well play an in- 
triguing role in tumor metastasis [31]. Therefore, agents that 
modify glycolipid metabolism would have wide biological ap- 
plication, especially in cell growth control. In our experiments, 
the levels of tamoxifen required to antagonize glycolipid bio- 
synthesis are well within the clinical range for reversing MDR. 
In the cell-free assay, we were able, with crude enzyme, to 
achieve enzyme inhibition in the micromolar ange, with cer- 
amide, the cosubstrate, present at a 20-fold excess. Although 
we have as yet to approach the structural requirements, from 
experiments with 4-hydroxy-tamoxifen, it appears that slight 
chemical modification can greatly influence activity (Table 1). 
A strong unifying aspect of this work and one that imports 
biological significance, is that of the relationship between hu- 
man melanoma, gangliosides, and the Dartmouth regimen. 
The Dartmouth, used to treat advanced stage melanoma, con- 
tains tamoxifen [12]; however, the role of tamoxifen in estro- 
gen receptor-independent cancers remains a curiosity. It is 
important to note that human melanoma express specific 
gangliosides, such as GD2, which increase as tumorigenesis 
progresses [32] and which may be associated with increased 
metastatic potential [31]. In this regard it would appear that 
tamoxifen imparts some therapeutic benefit via modification 
of glycolipid metabolism. This notion remains to be visited, 
but it is still tempting to throw out that agents regulating 
glycolipid metabolism, especially ceramide glycosylation, 
would be favorable models for drug design. 
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